Innovative Research Presentations at ISPE 2025
This year, Landmark Science is excited to showcase the power of real-world evidence at the upcoming ISPE 2025 conference, highlighting crucial insights around GLP-1 receptor agonists and Wegovy that are essential for Medicare influences and regulatory decision-making.
Landmark Science's Contributions
With a commitment to improving patient care through research, Landmark Science will collaborate with Innovaccer during the International Society for Pharmacoepidemiology (ISPE) 2025 annual conference. This significant event will occur over several days, bringing together thought leaders in the field of pharmacoepidemiology.
During the conference, Landmark Science will present its findings in five critical research pieces that center on GLP-1 receptor agonists (RAs) usage among patients. Their efforts are especially focused on Medicare patients and the urgent need for thorough investigative research in this area.
Understanding Patient Populations
The presented research casts a revealing light on the patient demographics initiating GLP-1 RAs, emphasizing the importance of understanding characteristics among Medicare beneficiaries. With GLP-1 therapies gaining traction for purposes extending beyond diabetes management, knowledge of patient profiles is increasingly vital.
CEO Shivani Aggarwal articulated the swift expansion of GLP-1 indications, acknowledging that concrete data is crucial for grasping utilization trends in Medicare. This insight is invaluable in shaping healthcare policies aimed at ensuring equitable access and optimal outcomes for beneficiaries.
Insights from the Conference
At ISPE 2025, Landmark’s team will offer detailed methodologies supporting their real-world evidence. Their studies are designed to bridge gaps in understanding how GLP-1 therapies are being used in practical settings, thereby informing regulatory frameworks and enhancements in patient care.
Research Focus Areas
Key highlight points of the presentations include:
- Two in-depth poster presentations focusing on GLP-1 RA usage among Medicare patients.
- Two additional posters that illustrate the potential of real-world evidence in aiding regulatory decision-making.
- A framework poster designed to guide submission success aligned with regulatory requirements.
Landmark encourages interested parties to engage with them at ISPE 2025, offering opportunities to connect and dive deeper into their findings and methodologies.
Participate and Learn More
Attendees are invited to arrange a meeting with the Landmark Science team to explore their abstracts, workshops, and other events slated for the conference. Stay updated by following their social media channels for real-time news and insights.
About Landmark Science, Inc.
Established as a leader in life sciences research, Landmark Science, Inc. dedicates itself to providing real-world evidence and health outcomes research solutions. Their services enable organizations to harness valuable RWE that contributes significantly to patient care strategies, regulatory affairs, and market accessibility. With a focus on tailored solutions for diverse client necessities, Landmark Science strives to deliver excellence in evidence-based research.
Frequently Asked Questions
What will Landmark Science present at ISPE 2025?
Landmark Science will focus on their research regarding GLP-1 receptor agonists and patient characteristics related to Medicare.
Why is real-world evidence important in medicine?
Real-world evidence is crucial as it provides insights into how treatments perform outside of clinical trials, guiding healthcare practices and policies.
How can I connect with Landmark Science during the event?
Attendees can schedule meetings with the Landmark Science team for discussions on their research and methodologies.
What is the significance of GLP-1 receptor agonists?
GLP-1 receptor agonists are significant for their expanding use in treating various conditions, including obesity, diabetes, and cardiovascular risks.
Where can I find more information about Landmark Science?
For more details about their research and services, visit their official website.
